Dr. Clement K. Chan, MD

Dr. Chan practices at Pacific Eye Institute, a Medical Group, Inc. in Palm Springs, California.

Dr. Chan's NPI, 1336131408, was assigned on August 16, 2005. Dr. Chan graduated from Loma Linda University School Of Medicine in 1980. Dr. Chan holds California license G45036.

Dr. Chan's primary practice is Pacific Eye Institute, a Medical Group, Inc., at 340 S Farrell Dr, Palm Springs, CA 92262 in Riverside County. The practice phone is (909) 982-8846.

Dr. Chan's primary practice is Pacific Eye Institute, a Medical Group, Inc. in Palm Springs, California. Dr. Chan is also affiliated with Desert Regional Medical Center. Dmand AI also links Dr. Chan to 1 more hospital, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chan practices, 3 sites in all. Vendor and product names are available with a free account.

Retina specialist is Dr. Chan's primary specialty in the NPI Registry, under taxonomy code 207WX0107X. Dr. Chan is board certified in ophthalmology by the American Board of Ophthalmology. Dr. Chan is licensed in California.

Dmand AI lists age-related macular degeneration, dry eye, eye infection or inflammation, glaucoma, hypertensive retinopathy, inflammation of iris, laser destruction of retinal or choroid lesions and retinal detachment among the conditions Dr. Chan treats.

CMS data shows 38,676 Medicare services from Dr. Chan across 19 procedure codes in 2024, for 828 Medicare patients. Medicare paid $2,851,108 for them. Every service was in an office.

CMS counts 828 Medicare patients who saw Dr. Chan in 2024. The largest group is 75 to 84, with 331 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 7% are also on Medicaid. Their average risk score is 1.50, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Chan's median patient age at 77, with 49% women.

In 2024, Dr. Chan wrote 1,071 Medicare Part D claims for 166 patients. 70% of them were for generic drugs. CMS names the drug for 1,028 of them, across 17 drugs with 11 or more claims each, at $49,604 in total drug cost. In 2023, CMS named 954 claims across 14 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 80 out of 100 for Dr. Chan for performance year 2024, reported as part of a group. Dr. Chan accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 76 papers to Dr. Chan, published from 2006 to 2022. 2020 was the busiest year, with 4. The most frequent topics are Visual Acuity, Tomography, Optical Coherence and Angiogenesis Inhibitors. Dr. Chan has published most often in Retina. Dr. Chan's most frequent co-authors are Steven G. Lin, MD, Prema Abraham, MD and Calvin Einar Mein, MD.

Dmand AI links Dr. Chan to 9 clinical trials, 2 of them phase 1/2 studies. Conditions studied include Macular Degeneration, Geographic Atrophy and Macular Edema. Jaeb Center for Health Research sponsors the most, 2. Open Payments lists research payments to Dr. Chan that name 2 trials.

CMS Open Payments shows 156 general payments to Dr. Chan from 17 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 58% of the total. Genentech, Inc. paid the most, $8,298. It also lists 16 research payments totaling $5,371 from 2016 to 2025, naming 2 clinical trials.

Dmand AI lists 14 awards for Dr. Chan, most recently Clinical Professor, Clinician Scientist in 2016.

Dr. Chan graduated from Loma Linda University School Of Medicine in 1980. Dr. Chan is a member of AAO and ACS.

Dr. Chan is in network with 11 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.